公司资料
Keros Therapeutics 股价、新闻与催化剂
- 股票代码:
- KROS
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
10.78 USD (-2.27%)
收盘价
最后更新: 2026年8月24日
209M USD
市值
股价为何变动
As of Aug 24, 2026, KROS closed down 2.27% at $10.78. No new same-company headline was identified in the current news window.
公司概览
TGF-β Biology Platform
Keros Therapeutics develops protein therapeutics for diseases linked to dysfunctional signaling within the transforming growth factor-beta family, which regulates muscle, bone, adipose tissue, cardiac tissue, and blood-cell development.
Rinvatercept
Rinvatercept is the company’s lead internally controlled candidate and is being developed for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Elritercept Partnership
Elritercept targets cytopenias, including anemia and thrombocytopenia, in myelodysplastic syndromes and myelofibrosis. Takeda has assumed development responsibility under a licensing partnership.
未来催化剂
- Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。